SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to reports of inevitable memory price hikes from industry leaders, fueling excitement over an AI-driven memory supercycle that has sent the stock to record highs. Community discourse is polarized between bulls celebrating institutional accumulation and historic momentum, and bears warning that current valuation levels and RSI extremes signal an impending bubble burst.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors discuss the potential for a major short squeeze and forced institutional buying ahead of the upcoming Russell index reconstitution. The community is actively debating the stock's long-term valuation and future pipeline catalysts, with many expressing high conviction in the company's immunotherapy technology despite recent price volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after announcing a multi-year joint research agreement with Honda to advance solid-state battery technology, validating the company's tech platform with a second major OEM. The community is actively discussing the strategic significance of this partnership, comparing it to ongoing collaborations with other automotive giants while debating the path toward commercial-scale manufacturing.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is generating significant market interest following a series of technical breakthroughs, including FDA clearance for an AI-powered gestational age tool and expanded government cloud authorizations. While community sentiment is divided between long-term investors tracking institutional backing and technical advancements, and traders wary of profit-taking pullbacks, the stock is trending as participants monitor its potential as an AI-driven platform play in the medical technology sector.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending due to strong demand for its fuel cell solutions as AI data centers face urgent power grid constraints. The community is actively discussing the company's massive contract backlog and its emergence as a critical backbone for AI infrastructure.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum driven by growing institutional interest and high expectations for upcoming Phase 3 trial data in non-small cell lung cancer (NSCLC) and the upcoming BLA filing. Community discourse is heavily focused on the stock's potential as a buyout target, with many participants viewing the current valuation as disconnected from the company's clinical progress and platform potential.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased investor optimism driven by positive clinical data for its subcutaneous Briumvi treatment and mounting speculation of a potential buyout from a major pharmaceutical player. The community is actively discussing the company's strong growth momentum, the potential for market share expansion in new indications, and the aggressive positioning of short sellers against a backdrop of institutional accumulation.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is trending as investors weigh a strong earnings and revenue beat against concerns over persistent weakness in discretionary IT spending and a pivot in corporate transparency regarding AI metrics. While record bookings and robust cash returns are supporting the stock, the community remains divided over whether the firm's pivot to agentic AI and cybersecurity acquisitions can effectively offset the structural disruption of its traditional consulting model.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is seeing heightened investor attention as the company navigates leadership transitions and market pressure from emerging satellite internet alternatives, while shareholders debate whether the current valuation offers a compelling value play given the reliable dividend and aggressive fiber infrastructure expansion.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is seeing intense volatility and aggressive buy-side momentum, fueled by its low public float and strategic backing from major industry players like IonQ and Dell. Investors are currently fixated on the company's positioning as a software-centric 'picks and shovels' play in the quantum computing sector, with many discussing the potential for a short squeeze despite concerns over insider ownership and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer...

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss...

TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits Expectations

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on...

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recom...

TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday

TScan Therapeutics (NASDAQ:TCRX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. One...

TScan Therapeutics (NASDAQ:TCRX) Shares Up 3%  - Here's What Happened

TScan Therapeutics (NASDAQ:TCRX) Stock Price Up 3% - Here's What Happened...

Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Hold" from the six brokerages that are currently covering the stock, Marketbeat.com...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Tscan Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.92
Prev Close	$0.8999
Open	$0.9112
Dividend Yield	0.00%
50-Day Moving Average	$1.09
Beta	1.37
Avg. Volume	671,494.18
PE Ratio	-0.94

52-Week High	$2.57
52-Week Low	$0.8481
Market Capitalization	$58.81M
EPS (Annual)	-$0.9999
Price to Book	0.56
Revenue Per Employee	$72,711.27

TCRXTscan Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCRX News